Nanosonics is entering a new phase of growth with the commercial launch of CORIS, its second major platform product, marking the most significant transformation since establishing trophon as the standard for ultrasound probe disinfection. The company’s FY26 results show solid fundamentals underpinning this expansion, with revenue reaching $203.9 million, up 3 percent year-on-year and 6 percent in constant currency terms. This layered performance reflects both the maturity of the core trophon business and early-stage investments flowing into CORIS commercialization.
Trophon remains the earnings foundation, with 39,230 units in its cumulative installed base and protecting approximately 31 million patients annually from ultrasound probe cross-contamination. The platform has established itself as the standard of care, delivering steady performance across North America, Europe, and Asia Pacific. Gross profit climbed to $156.8 million with 6 percent constant currency growth, suggesting the core business maintains strong unit economics despite modest top-line expansion. The gap between revenue growth and gross profit growth in constant currency reflects underlying resilience in pricing and mix, even as organic unit sales decelerate from earlier growth rates.
CORIS represents the real strategic catalyst. The flexible endoscope market is substantially larger than the installed ultrasound probe universe, with millions of procedures annually requiring cleaning and disinfection. Unlike trophon, which addressed a fragmented, manual process with significant variability, endoscopy has never benefited from a validated, automated standard. If CORIS gains adoption at even a fraction of trophon’s penetration rate, the company’s addressable market and long-term growth profile could reshape considerably. This is the transformation management references in the annual report.
Operationally, Nanosonics managed expenses well, keeping operating expenditure at $141.4 million despite ongoing investment in CORIS launch activities. Profit before tax grew 10 percent year-on-year to $20.1 million, or 15 percent in constant currency, indicating improving operational leverage. Cash and cash equivalents stood at $155.2 million, providing substantial capacity to fund CORIS expansion without straining the balance sheet. The company also returned $20 million to shareholders through buyback, signaling management confidence in future cash generation.
For investors, execution on CORIS is now the principal watch. Early adoption in endoscopy can be slow given entrenched workflows and surgeon preferences, creating visibility risk over the next two to three years. Trophon should continue generating steady cash, but investors should expect margin rather than acceleration from that platform. Watch quarterly updates on CORIS unit installations, management commentary on pipeline conversations with hospital systems, and any guidance adjustments around commercialization timeline. The company’s trophon track record suggests execution competence, but CORIS operates in a different competitive and regulatory environment that will test management’s ability to replicate that success.
View the full ASX announcement (PDF)
About Nanosonics Ltd (ASX: NAN)
Nanosonics Ltd is an Australian healthcare company that manufactures and distributes ultrasound probe disinfectors and related infection prevention technologies. The company’s flagship product, Trophon, is designed to reduce healthcare-acquired infections through high-level disinfection of ultrasound probes. Nanosonics operates across Australia, the United States, Canada, the United Kingdom, and Europe, serving the healthcare sector globally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
